Updates are available Erratum dated 2017-09-26

Article History

Received: 28 March 2017

Accepted: 9 June 2017

First Online: 2 August 2017

Change Date: 26 September 2017

Change Type: Erratum

Change Details: An erratum to this article has been published.

Funding

: The sponsor of the trial was the Type 1 Diabetes TrialNet Study Group. Type 1 Diabetes TrialNet Study Group is a clinical trials network funded by the National Institutes of Health (NIH) through the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Allergy and Infectious Diseases and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (through the cooperative agreements U01 DK061010, U01 DK061034, U01 DK061042, U01 DK061058, U01 DK085465, U01 DK085453, U01 DK085461, U01 DK085466, U01 DK085499, U01 DK085504, U01 DK085509, U01 DK103180, U01 DK103153, U01 DK085476, U01 DK103266, U01 DK103282, U01 DK106984, U01 DK106994, U01 DK107013, U01 DK107014, UC4 DK106993) and JDRF. The content of this review is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or JDRF.

: MSA owns stocks of Medtronic. ÅL is a member of the Scientific Advisory Board of Diamyd Medical, Stockholm, Sweden. CJG is a consultant for Bristol-Myers Squibb and receives research funding from Janssen. All other authors declare that there is no duality of interest associated with their contributions to this manuscript.

: MB and MP drafted the article. All other authors revised it critically for important intellectual content. All authors approved the final version.